Since the first case of COVID-19 was diagnosed in Wuhan, China, in December 2019, COVID-19 cases rose rapidly across the globe. On March 11, 2020, World Health Organization (WHO) officially declared that COVID-19 is a pandemic.
Over 1,200 clinical trials worldwide have either been disrupted by COVID-19 due to suspended enrollment or delayed initiation or have been impacted by slow enrollment. Regulatory guidance has been issued for industry, investigators, and institutional review boards on conducting clinical trials during the COVID-19 pandemic, including suggested methods such as virtual visits, phone interviews, self-administration, and remote monitoring These suggestions could help trials that are being met with subject quarantine, travel limitations, clinical site closures, and interrupted supply chains.
The Coronavirus Disease 2019 (COVID-19) impact on clinical trials market research report gives an important update to the previous year with expert analysis on how COVID-19 is impacting clinical trials and the potential move toward decentralized clinical trials (DCTs).
The overall objective of the 2022 survey was to update and expand the understanding of the impact of COVID-19 on clinical trials and the industry’s view on adapting to DCTs. DCTs allow the collection of safety and efficacy data from study participants by using a range of digital technologies that require a minimum number of site visits. This can include telemedicine, wearable devices, eConsent, electronic clinical outcome assessments, and electronic health records.
The specific objectives of the 2022 survey were to:
- Update to current perceptions as compared to this same report published in August 2021 and August 2020
- Benchmark the companies’ primary concerns
- Determine the impact of COVID-19 to date on clinical trials
- Assess companies’ future plans to use DCTs
- Track changes to clinical trial strategy and attitudes
A total of 103 GlobalData Pharma clients and prospects from around the world participated in the seven-minute survey, which was fielded from June 29, 2022, to July 28, 2022. This report includes and is based on industry opinions on COVID-19’s impact on clinical trials and the use of DCTs.
Survey Respondent Mix
For more insights on how COVID-19 is impacting the clinical trial sector, download a free report sample
Clinical trial disruption remains steady and slow enrollment continues to increase: The impact on clinical trial participants and the safety of patients were viewed as major and legitimate concerns. Currently, organizations are utilizing remote patient monitoring to mitigate clinical trial disruptions as a first step, but a plan to move toward DCTs will be the next step.
To know more about key findings, download a free report sample
Reasons to Buy
- Understand companies’ primary concerns about the COVID-19 pandemic.
- Determine the impact of COVID-19 to date on clinical trials.
- Assess companies’ future plans to use decentralized clinical trials.
- Track changes to clinical trial strategy and attitudes.
Table of Contents
Table of Contents (PowerPoint Deck)
1 Study Design
1.2 Objectives and Design
1.3 Respondent Mix
1.4 Respondent Profiles
2 Key Findings
3 Primary Business and Clinical Trial Concerns
3.1 Primary Business Concerns
3.2 Primary Clinical Trial Concerns
3.3 Clinical Trial Disruptions
3.4 Addressing Clinical Trial Disruptions
4 Movement Toward Decentralized Trials
3.1 Therapy Areas Most Suited to Decentralized Trials
3.2 Pre-pandemic Decentralized Trials Use
3.3 Post-pandemic Decentralized Trials Use
3.4 Future Movement Toward Decentralized Clinical Trial Use
3.5 Cost Comparison
4 Challenges Facing Decentralized Trials
4.1 Biggest Changes
4.2 Biggest Considerations
4.3 Biggest Challenges
4.4 Risk Deviations
5 Summary of Key Findings
7 Contact Us
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Personal and transaction information are kept safe from unauthorised use.
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.